Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

Pfizer TodayPFEPfizer$28.22 +0.24 (+0.86$25.20▼$37.80Dividend Yield5.95$35.54Add to WatchlistPharmaceutical giant Pfizer Inc. NYSE: PFE has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO and Mounjaro and Zepbound makers Eli Lilly & Co. NYSE: LLY. Pfizer had failed in its previous attempts to create a viable GLP-1 contender. Pfizer operates in the medical sector. In addition to the incu ...